3d
Zacks Small Cap Research on MSNACHV: 2Q:25 NDA SubmissionACHV READ THE FULL ACHV RESEARCH REPORT Achieve Life Sciences, Inc. (NASDAQ:ACHV) reported 2024 results sharing progress with ...
Treatments for dry eye disease, neuroendocrine tumors, chronic spontaneous urticaria, Barth syndrome, and migraine are under review.
Ardelyx (ARDX) announced the approval of a New Drug Application, NDA, by China’s Center for Drug Evaluation of the National Medical Products Administration for tenapanor to control serum ...
10d
Pharmaceutical Technology on MSNIndonesia approves Antengene’s Xpovio NDA for multiple indicationsAntengene’s new drug application (NDA) for Xpovio (selinexor) has gained approval from the Indonesia National Agency of Drug ...
The FDA has set a PDUFA target action date of October 23, 2025, for the low-dose atropine formulation.
Corcept Therapeutics (CORT) announced that the FDA filed its New Drug Application (NDA) submission for its proprietary, selective cortisol ...
The FDA is reviewing the supplemental NDA for cabozantinib in adults with ... The Company is seeking approval for acute treatment of migraine with or without aura.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results